

616.12-008.331.1+616.61-08

© . . . , . . . , . . . , 2012.

,

()

. . . , . . . 2, . . . «
. . . ».

: , , , , .

()

. . . , , . . . per se.

()

, [13]. , , -

()

10-30%.,

()

[5, 7, 19].

(),

, / , -

, , -

). (, - [2, 7,

12, 17, 25].

, : -

, , , -

[6, 17].

,
 :
 2⁻, N-
 ,
 300 [1, 9, 19].
 (20-200 /) 30-300 /
 , ()
 ()
 30% 3
 10-
 2⁻
 N- ()
 () 60%)
 25%
 [6, 8, 15, 23].
 /) [1, 21, 28].
 () , ..
 [11, 23]. [21].
 (3) : (2004)
 <60 / ; >265 /
 >300 / ,
 >200 / 3
 [15, 19]. [21, 28].
 II (),
 (2003), II,
 (2004)
 <130/80
 >1,0 / - <125/75
 <110
 [4, 14, 18, 21]. /

() , , -) 5
98% , (75%) , , -
[1, 10].
(). (2004)
, , ,
() II ,
: , , ,
, , ,
, , ,
[5, 6, 14, 21].
()
, , ,
- , , ,
ALTIMUDE 8600 ,
: , , ,
[16, 20, 22, 27, 30].
()
, , ,
, , ,
1235 ,
6- 64% [3, 6].
ESH/ESC
()
, , , :
, , ,
[5, 21].
, , ,
11

2. -

3. -

2,0 / (177 /

) <30 / . [3, 5, 6].

1. -

i .-2009.- 4.- .32-34. //

2. -

3. .-2011.- 4.- .30-32. //

4. .-2011.- 384 . [.].

55 (ONTARGET) [21, 24, 26, 29].

« .-2010.- 4.- .20-24. //

5. -

6. .-2010.- 200 .

7. .-2009.- 376 .

ASCOT(+)

8. .-2007.- 6.- .39-46. //

[6, 21].

9. i i i i «

30 2003 65/462. »

10. -

([3, 6, 21].)

11. « .-2010.- .12, 1.- .15-19. //

1. 10-30% // « .-2010. .13, 4.- .40-44. //

12. :[]/ . .-2010.- 800 .

13. -

14. microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes / M. C. Foster, S. L. Hwang, M. G. Larson // Archives of Internal Medicine. -2007. Vol. -167, 6, . 1386-1392.
15. 03.07.2006– . . . ,2006. - 55 . 436
24.Mann J. F. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (ONTARGET study): a multicentre, randomised, double – blind, controlled trial / J. F. Mann, R. E. Schmieder, I. Dyal, et al. //The Lancet. –2008. Vol. -372. –p. 547-553.
16. – ,2006. – 38 .
25.Murea M. Essential hypertension and risk nephropathy: a reappraisal / M. Murea, B. I. Freedman / Current Opinion in Nephlogy and Hypertension. -2010. - 19.– . 235-241.
- 17.A. Levey. Chronic kidney disease / A. Levey, J. Coresh //The Lancet. –2012. –Vol. 379, 9811. –p. 165-180.
- 18.Appel L. J. Intensive blood-pressure control in hypertensive chronic kidney disease / Appel L. J., et al. for the AASK Collaborative Research Group. //New England Journal of Medicine. 2010. – Vol. 363. –p. 918-929.
- 19.Bertrand M. E. Reduction in mortality with anti-hypertensive agents. Evidence from clinical trials in at – risk hypertensive patients / M. E. Bertrand, J. J. Mourad // European Heart Journal. 2010. – Vol. 31. – p. 321-322.
- 20.Carey R. M. Antihypertensive and renoprotective mechanism of rennin inhibition in diabetic rats / R. M. Carey // J. Hypertension. – 2008. Vol. 52, 1, p. 63-64.
- 21.2007 European Society of Hypertension – European Society of Cardiology guidelines for management of arterial hypertension / J. Hypertension. –2007. Vol. 25. –p. 1105-1187.
- 22.Feldman D. L. New insights into the renoprotective actions of the rennin inhibitor aliskiren in experimental renal disease / D. L. Feldman // Hypertension Research. 2010. - 33. – p. - 279-287.
- 23.Foster M. C. Cross – classification of
26.ONTARGET Investigators. Telmisartan, ramipril, or both, in patients in high risk for vascular events / New England Journal of Medicine. – 2008. – Vol. 358. – p. 1547-1559.
- 27.Pimenta E. Role of aliskiren in cardio-renal protection and use in hypertensive with multiple risk factors // Pimenta E., Oparil S. // Therapeutics and Clinical Risk Management. – 2009. Vol. 5. – p. 459-464.
- 28.Ruilope L. Blood pressure lowering or selection of antihypertensive agent: wich is more important? / Ruilope L., Segura J. // Kidney International. – 2006. – Vol. 21, 4. – . 843-846.
- 29.Verrill T. A. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease / T. A Verrill, P. A. McCuullough / Postgraduate Medical Journal. –2010. Vol. 122. –p. 25-34.
- 30.Wiggins K.J. Aliskiren: a novel renoprotective agent or simply an alternative to ACE ingibitors / K. J. Wiggins, D. J. Kelly // Kidney International. – 2009. – Vol. 76, 1. – . 23-31.